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Although mutations of BRCA2 are known to be asso-
ciated with increased risks of prostate and pancreas can-
cer and melanoma, the prevalence of Jewish founder
mutations of BRCA1 and BRCA2 (JFM’s) amongst inci-
dental cases of these malignancies in Ashkenazi Jews
has not be shown to justify founder mutation testing.
This case report highlights the need to consider combi-
nations of these cancers in Ashkenazi families.
John* (*pseudonyms), aged 63, presented to the Heredi-
tary Cancer Clinic at Prince of Wales Hospital. All four
grandparents were Ashkenazi Jewish, and he became
aware of BRCA1and BRCA2 JFM testing following the
identification of the BRCA2 founder mutation in the hus-
band of his sister Judy*. John’sb r o t h e rh a dd i e df r o m
pancreas cancer at 60, his father had died from prostate
cancer at 69 and his uncle had died from melanoma at
60. John was known to have an elevated PSA and was
being treated for benign prostatic hypertrophy. There
were no cases of breast or ovarian cancer in his family.
The combination of cancers was sufficiently concern-
ing to offer John founder mutation testing. The
6174delT mutation of BRCA2 was identified. It was also
identified in his sister Judy. Despite having a husband
w i t ht h es a m em u t a t i o n ,s h eh a dt h r e ea d u l tc h i l d r e n
with no evidence of Fanconi Anaemia. John’sm o t h e r
was shown not to carry the mutation, so predictive test-
ing was offered to his paternal relatives.
To date, 14 people in this family have had predictive
testing and 5 unaffected carriers have been identified. In
view of his mutation result, John underwent a further
prostatic biopsy and cancer was found, resulting in a
prostatectomy. Two unaffected relatives have had RRSO,
one was shown to have dysplastic changes in the fallo-
pian tube. Eligible tested males have been enrolled in
the IMPACT study. Mutation carriers in this family
aged between 40 and 80 have been offered participation
in a trial of pancreatic cancer screening with endoscopic
ultrasound.
Although this family had no cases of breast or ovarian
cancers, it indicates that combinations of cancers asso-
ciated with BRCA2 need to be considered for testing.
Despite this being a large pedigree with information
about the cancer status of all members, the paternal
great grandparents of the proband had 38 descendents
in the next 3 generations, of whom only 11 were female,
contributing to the absence of any history of breast and
ovarian cancer. Families such as this highlight the need
to consider population JFM testing, which is being
trialled in the UK as the GCaPPS (Genetic Cancer Pre-
diction Through Population Screening) study, and being
considered for Sydney through the POWH.
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